Bitwise Files for XRP ETF Following Key Approvals
Bitwise seeks to launch an XRP ETF after SEC's approval of Bitcoin and Ethereum ETFs, hoping to attract significant investments.
- Latest
- Trending
Bitwise seeks to launch an XRP ETF after SEC's approval of Bitcoin and Ethereum ETFs, hoping to attract significant investments.
Biotech and AI sectors see major funding, with Candid Therapeutics' $370M and Glean's $260M rounds leading the way this week.
Over 103 million Dogecoin moved from bankrupt Bittrex, raising questions about future impacts on DOGE's market dynamics.
Tesla's legal battle on CEO pay may redefine corporate law on shareholder vs. judicial authority.
Delaware releases new guidance for schools on AI use, covering implementation, ethics, and learning integration strategies.
WSFS Financial's strong ratings affirmed by KBRA, highlighting stability in earnings, liquidity, and diversified income.
CTT Pharmaceutical CEO buys $70 in stock, signaling confidence. Despite recent gains, profitability concerns remain. Investors should monitor closely.
"Coupang Director Benjamin Sun sells $14.44M in stock, signaling optimism despite challenges. Q1 2024 shows 33% revenue rise, boosting investor ...
"Jeffrey H. Margolis of Alignment Healthcare sells 1,200 shares worth $9,672. Despite insider sale, company sees 50% membership increase."
E3technology enhances Empore™ membranes for better proteome sample prep, crucial for low-cell proteomics, say experts at UD and CDS Analytical.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.